X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Xediton is responsible for the registration and commercialization of BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products in Canada.
Lead Product(s): Delafloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Baxdela
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Melinta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 15, 2023
Details:
Under the terms of the license and distribution agreement, Helsinn Healthcare SA grants Xediton an exclusive license to distribute, promote, market, and sell TRUSELTIQ in Canada and Helsinn will supply TRUSELTIQ for commercialization in Canada.
Lead Product(s): Infigratinib
Therapeutic Area: Oncology Product Name: Truseltiq
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Helsinn Advanced Synthesis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
